Strategic Initiative

Slingshot members are tracking this corporate initiative:

Bristol-Myers Squibb (BMY) Enters Collaboration Agreement with Calithera Biosciences (CALA) to Evaluating Opdivo + CB-839 in Clear Cell Renal Cell Carcinoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Dec 21, 2016
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Collaboration Agreement, Opdivo, Cb-839, Clear Cell Renal Cell Carcinoma